Literature DB >> 31213382

Risk factors of hospital mortality in chronic subdural hematoma: A retrospective analysis of 1117 patients, a single institute experience.

Shen Wang1, Yuxiao Ma1, Xiaochun Zhao2, Chun Yang1, Jiacheng Gu1, Weiji Weng3, Jiyuan Hui4, Qing Mao4, Guoyi Gao1, Junfeng Feng5.   

Abstract

Chronic subdural hematoma (CSDH) is not a benign disease in the elderly, and the mortality of CSDH is reported to be up to 32%. The study aimed to analyze hospital mortality and evaluate the risk factors in patients with CSDH. We retrospectively reviewed all patients with CSDH treated in the neurosurgery department of Renji hospital, School of Medicine, Shanghai Jiao Tong University from 10/2003 to 10/2018. Univariate and multivariate logistic regression analyses on the factors, including gender, age, Glasgow Coma Scale (GCS) on admission, main symptoms, history of head trauma, location of hematoma, density of subdural hematoma, laboratory tests on admission, et al, were performed. A total of 1117 patients with CSDH were included in the study, among which 20 patients died (mortality rate: 1.8%). Comparing the survival group and the death group, gender (p < 0.01), GCS on admission (p < 0.01), impaired consciousness as the presenting symptom (p = 0.041), history of head trauma (p = 0.02), location of hematoma (p = 0.03), platelet (p < 0.01), prealbumin (p = 0.046), albumin (p < 0.01), international normalized rate (INR) (p = 0.03), high sensitivity C-reactive protein (hsCRP) (p < 0.01), postoperative hyperthermia (p < 0.01) were shown to have significance. The logistic regression analysis revealed that GCS on admission (odds ratio [OR] 0.077, p < 0.01), bilateral CSDH (OR 0.100, p < 0.01 left CSDH as reference), prealbumin (OR 0.137, p = 0.02), INR (OR 12.959, p < 0.01) and hsCRP (OR 8.397, p < 0.01) were significantly associated with a higher mortality rate in CSDH. GCS on admission, bilateral CSDH, prealbumin, INR and hsCRP might be independent predictors of CSDH mortality.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic subdural hematoma; High sensitivity C-reactive protein; Hospital mortality; International normalized rate; Prealbumin; Risk factors

Mesh:

Substances:

Year:  2019        PMID: 31213382     DOI: 10.1016/j.jocn.2019.06.026

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  6 in total

1.  Awake surgery in sitting position for chronic subdural hematoma.

Authors:  Milan Lepić; Stefan Mandić-Rajčević; Goran Pavlićević; Nenad Novaković; Lukas Rasulić
Journal:  Acta Neurochir (Wien)       Date:  2021-01-19       Impact factor: 2.216

2.  A Single-Center Analysis of Sex Differences in Patients With Chronic Subdural Hematoma in China.

Authors:  Yunwei Ou; Wenhua Fan; Xiaofan Yu; Liang Wu; Weiming Liu
Journal:  Front Neurol       Date:  2022-05-17       Impact factor: 4.086

3.  Role of the patient comorbidity in the recurrence of chronic subdural hematomas.

Authors:  Rafael Martinez-Perez; Asterios Tsimpas; Natalia Rayo; Santiago Cepeda; Alfonso Lagares
Journal:  Neurosurg Rev       Date:  2020-03-07       Impact factor: 3.042

4.  Management of chronic subdural hematoma: A study from Jordan.

Authors:  Sultan Jarrar; Mohammed M Al Barbarawi; Suleiman S Daoud; Qais A Samara; Aref A Qarqash; Rama J Alawneh; Nancy A Abu-Amoud; Obada E Ababneh; Omar F Jbarah
Journal:  J Taibah Univ Med Sci       Date:  2022-07-09

5.  Predicting Chronic Subdural Hematoma Recurrence and Stroke Outcomes While Withholding Antiplatelet and Anticoagulant Agents.

Authors:  Mario Zanaty; Brian J Park; Scott C Seaman; William E Cliffton; Timothy Woodiwiss; Anthony Piscopo; Matthew A Howard; Kingsley Abode-Iyamah
Journal:  Front Neurol       Date:  2020-01-15       Impact factor: 4.003

6.  A matter of frailty: the modified Subdural Hematoma in the Elderly (mSHE) score.

Authors:  Silvia Hernández-Durán; Daniel Behme; Veit Rohde; Christian von der Brelie
Journal:  Neurosurg Rev       Date:  2021-07-06       Impact factor: 2.800

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.